PILA PHARMA AB (SE0015988274) — research page
SE · se-cm-kg/SSME/SE0015988274 · as of 2026-11-06
Identity and listing
The issuer is PILA PHARMA AB, listed on First North Sweden under ticker SE0015988274. Its ISIN is SE0015988274 and its LEI is 6488Z7WG18Q0ZN0V0262. The security type, segment, sector and jurisdiction are not on the record. The listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | PILA PHARMA AB | source · 2026-11-06 |
| exchange | First North Sweden | source · 2026-11-06 |
| ticker | SE0015988274 | source · 2026-11-06 |
| ISIN | SE0015988274 | source · 2026-11-06 |
| LEI | 6488Z7WG18Q0ZN0V0262 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-09 |
The disclosure read
The record holds 35 filings in the twelve months to 2026-11-06, across 28 filing days. The median gap between filing days is 11 days. The latest filing is dated 2026-11-02, is of type Investor News, and is 4 days before the record date. The median gap between filing days for First North Sweden is 11 days across 325 issuers, the median filings count is 21, and the median latency is 7 days. The sector median is not on the record.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 35 | 11 | 4 |
| exchange median: First North Sweden (325 issuers) | 21 | 11 | 7 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-02 | Investor News | Investor News | PILA PHARMA: TO PARTICIPATE AT BIO EUROPE, A PHARMA PARTNERING CONFERENCE IN COLOGNE, NOVEMBER 9-11, TO EXPAND PARTNERSHIP DIALOGUE AS CLINICAL DEVELOPMENT PROGRESSES |
| 2026-10-12 | Company Announcement | Company Announcement | PILA PHARMA: FIRST SUBJECTS DOSED IN SAFETY PART 1 OF PP-CT04, A CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY |
| 2026-09-30 | Company Announcement | Company Announcement | PILA PHARMA: FIRST SUBJECT FIRST VISIT COMPLETED FOR SAFETY PART 1 OF PP-CT04, A CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY |
| 2026-09-29 | Company Announcement | Company Announcement | PILA PHARMA: FIRST CLINICAL SITE INITIATED AND ACTIVATED, ENROLLMENT COMMENCES FOR SAFETY PART 1 OF PP-CT04, A 12-WEEK CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY |
| 2026-09-08 | Investor News | Investor News | PILA PHARMA: ALL RECENT H1 REPORT AND MANAGEMENT INTERVIEWS NOW ONLINE |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is not on the record, and its location is not on the record. Auditor changes are not on the record, because the market's record does not carry a lifecycle type map for this register.
Events and halts
The record does not carry listing, delisting, name change, domicile change or segment move events, because the market's register has no lifecycle type map. The halt flag is listed, not halted.
Orderability
The orderability outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.
rule acm-68000/se/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's investor-relations page names 8 research houses: Redeye Equity Research, AktieInfo Equity Research, AG Equity Research, Carlsquare Equity Research, Redeye Equity Research Sweden, AktieInfo Equity Research Denmark, AG Equity Research Sweden and Carlsquare Equity Research Sweden.
| research house | analyst | source · read date |
|---|---|---|
| Redeye Equity Research | Filip Einarsson | issuer page · 2026-11-12 |
| AktieInfo Equity Research | John Stihøj | issuer page · 2026-11-12 |
| AG Equity Research | Axel Ljunghammer | issuer page · 2026-11-12 |
| Carlsquare Equity Research | Niklas Elmhammer | issuer page · 2026-11-12 |
| Redeye Equity Research Sweden | Filip Einarsson | issuer page · 2026-11-12 |
| AktieInfo Equity Research Denmark | John Stihøj | issuer page · 2026-11-12 |
| AG Equity Research Sweden | Axel Ljunghammer | issuer page · 2026-11-12 |
| Carlsquare Equity Research Sweden | Niklas Elmhammer | issuer page · 2026-11-12 |
Open research
No openly published research notes were found on the record.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No issuer years are sealed. The market's earliest sealed date is not on the record, and the live record began is not on the record.
Sources
7 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.se-cm-kg.ai/events/SSME/SE0015988274 (the disclosure lines)
- 10.4
- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)
- 10.5
- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.6
- https://pilapharma.com/analyst-coverage/ (coverage)
- 10.7
- https://mcp.se-cm-kg.ai/record/SSME/SE0015988274 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"SE0015988274"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:c474d848892278c9.